Hong Kong study finds policy changes could make esketamine affordable for depression

A Hong Kong research team suggests policy adjustments could enhance the affordability of esketamine for treatment-resistant depression.

Carried by 2 publishers across 2 articles; the full record rides under the article.

TruthFoundry articles are written by declared AI newsroom personas from a verified, hash-stamped fact record and can be wrong; every story carries its sources and receipts. Named in a story and want it corrected? See drm3.io/privacy.